- 2,522
- 12
FTW!
OFFICIAL STOCK MARKET & ECONOMY THREAD VOL. SCHOOL'S OUT
- Thread in 'General' Thread starter Started by dey know yayo,
- Start date
- 3,223
- 2,309
GFG!
Bought in @ .29 AH other day
Bought in @ .29 AH other day
- 2,522
- 12
ASFX
- 3,223
- 2,309
I saw ASFX earlier at .0066 and told my boy to get in. He's in at .0073. He owes me commission for that pick...
- 493
- 10
damn, my bio/pharm boy told me about this one. i didn't get in.
ACTC is his next in line. Stem Cell Co.
- 2,522
- 12
concensus on CTIC
- 493
- 10
614%...jesus.
- 493
- 10
i sold @ 1.8, bought back in @ 1.7.
- 7,568
- 32
anyone get in on ASFX?
- 2,522
- 12
what's your target?
- 1,531
- 10
Originally Posted by iEternalv
ctic on its way to approval this weekend...hopefully.
i hope you have all joined me in riding the rocket-ship to $3+
bought my shares at 1.53 ...would love to at least double my money
what is a good stock screener? I looked at some free ones using google but none of them seemed to work like how some of you guys are saying...
-J23C
- 3,223
- 2,309
Uh oh...
Guaranty Bank, an Austin-based savings institution with $13.5 billion in assets, is expected to be seized by the FDIC by the end of theweek.
So glad I took profit and got out today.
Guaranty Bank, an Austin-based savings institution with $13.5 billion in assets, is expected to be seized by the FDIC by the end of theweek.
So glad I took profit and got out today.
- 859
- 10
jmba releases earnings tomorrow.
anybody have any predictions?
anybody have any predictions?
- 3,223
- 2,309
Do you have a position in JMBA?
- 3,223
- 2,309
For those holding CTIC
Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
PR Newswire
August 19, 2009: 04:52 PM ET
SEATTLE, Aug. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into anagreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to asingle institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, intoapproximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
In connection with the offering, the investor received warrants to purchase up to 4,713,276 shares of common stock. The warrants have an exercise price of$1.70 per warrant share, for total potential additional proceeds to the Company of approximately $8.0 million upon exercise of the warrants. The warrants areexercisable immediately upon issuance and terminate nine months after the date of issuance.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include, among other things, payinginterest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing ofnew drug applications, and general working capital.
Shares of the Series 2 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have novoting rights on general corporate matters.
The closing of the offering is expected to occur on August 24, 2009, at which time the Company will receive the cash proceeds and deliver the securities.
Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent forthe offering.
A shelf registration statement relating to the shares of Series 2 Preferred Stock and warrants issued in the offering (and the shares of common stock issuableupon conversion of the Series 2 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC").The shelf registration statement was automatically effective upon filing with the SEC. A prospectus supplement relating to the offering will be filed with theSEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the followingaddress: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor asolicitation of an offer to buy any of our shares of Series 2 Preferred Stock or warrants. No offer, solicitation or sale will be made in any jurisdiction inwhich such offer, solicitation or sale is unlawful.
Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
PR Newswire
August 19, 2009: 04:52 PM ET
SEATTLE, Aug. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into anagreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to asingle institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, intoapproximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.
In connection with the offering, the investor received warrants to purchase up to 4,713,276 shares of common stock. The warrants have an exercise price of$1.70 per warrant share, for total potential additional proceeds to the Company of approximately $8.0 million upon exercise of the warrants. The warrants areexercisable immediately upon issuance and terminate nine months after the date of issuance.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include, among other things, payinginterest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing ofnew drug applications, and general working capital.
Shares of the Series 2 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have novoting rights on general corporate matters.
The closing of the offering is expected to occur on August 24, 2009, at which time the Company will receive the cash proceeds and deliver the securities.
Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent forthe offering.
A shelf registration statement relating to the shares of Series 2 Preferred Stock and warrants issued in the offering (and the shares of common stock issuableupon conversion of the Series 2 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC").The shelf registration statement was automatically effective upon filing with the SEC. A prospectus supplement relating to the offering will be filed with theSEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the followingaddress: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor asolicitation of an offer to buy any of our shares of Series 2 Preferred Stock or warrants. No offer, solicitation or sale will be made in any jurisdiction inwhich such offer, solicitation or sale is unlawful.
- 21,365
- 812
some believe that stock could see 0.05-0.10.Originally Posted by nicefro
ASFX
- 2,522
- 12
Sounds like good news.
- 2,522
- 12
I wouldn't bet on it. It just irks me to see/invest these securities valued at under a penny.Originally Posted by finnns2003
some believe that stock could see 0.05-0.10.Originally Posted by nicefro
ASFX
- 6,782
- 18
If you see it around 1.65 or less, buy. If you want it regardless, buy before the close on Friday.
Monday will be too late.
- 1,296
- 11
And thus, the FDIC is just about bankrupt.
- 2,522
- 12
MFA looking bullish.
- 2,522
- 12
MHS
- 493
- 10
ugh, after hours didn't look too good. if it drops tomorrow i'm buying this up more. up almost ~$65k on CTIC now.
I see this short term in the $3 range, and a little longer $5 to even $10. call me crazy, but if they get the drugs through and running, it's a big deal.
- 4,122
- 640
word to dndn
- 493
- 10
if it goes to 20 i will throw a party in vegas for all the regulars here.
